Artwork

内容由OncoPharmPod and John Bossaer提供。所有播客内容(包括剧集、图形和播客描述)均由 OncoPharmPod and John Bossaer 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Cross-Trial Comparison Don'ts

19:31
 
分享
 

Manage episode 435628516 series 1848091
内容由OncoPharmPod and John Bossaer提供。所有播客内容(包括剧集、图形和播客描述)均由 OncoPharmPod and John Bossaer 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
We all know we aren't supposed to make cross-trial comparisons, but it happens anyway. So, let's compare FLARUA2 (osimertinb + chemo) and the newly FDA-approved MARIPOSA regimen (lazertinib + amivantamab) to see what we can (and can't) take away from such a dangerous cross-trial comparison.
  continue reading

354集单集

Artwork

Cross-Trial Comparison Don'ts

OncoPharm

59 subscribers

published

icon分享
 
Manage episode 435628516 series 1848091
内容由OncoPharmPod and John Bossaer提供。所有播客内容(包括剧集、图形和播客描述)均由 OncoPharmPod and John Bossaer 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
We all know we aren't supposed to make cross-trial comparisons, but it happens anyway. So, let's compare FLARUA2 (osimertinb + chemo) and the newly FDA-approved MARIPOSA regimen (lazertinib + amivantamab) to see what we can (and can't) take away from such a dangerous cross-trial comparison.
  continue reading

354集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南